SAFC has announced investments totaling $75 million during the past year to expand HPAPI capacity. Those include a $4.5-million project to add a cGMP pilot plant and kilo-lab capacity at Madison, completed earlier this year; a $29-million investment to expand bacterial and fungal fermentation derived HPAPI capacity at Jerusalem, due for completion in 2009; and a $30-million investment to build a commercial-scale HPAPI facility at Madison, due to be completed by year-end 2009.
About SAFC: SAFI(R) is the custom manufacturing and services group within Sigma-Aldrich that focuses on high-purity inorganics for high technology applications, cell culture products and services for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials. SAFC has four focus areas - SAFC Pharma(TM), SAFC Supply Solutions(R), SAFC Biosciences(TM), and SAFC Hitech(TM) - and had annual sales of nearly $600 million in 2007. SAFC is one of the world's 10 largest fine chemical businesses. For more information, visit http://www.safcglobal.com.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company. Its biochemical and organic chemical products and kits
are used in scientific and genomic research, biotechnology, pharmaceutical
development, the diagnosis of disease and as key components in
pharmaceutical and other high technology manufacturing. The Company has
customers in life science companies, university and government
institutions, hospitals, and in industry. Over
'/>"/>
| SOURCE Sigma-Aldrich Copyright©2008 PR Newswire. All rights reserved |